jakafi sale track multipl catalyst
jakafi track meet full-year guidanc
jakafi revenu slightli light consensu note
inventori draw due unexpect destock follow price increas taken
septemb impact sale low end full-year sale guidanc rais
concern continu jakafi momentum patient demand remain
strong myelofibrosi mf polycythemia vera pv grow y-o-i
respect believ revenu beyond remain strong
addit new indic though gross net may impact increas
patient drug product royalti jakavi olumi
respect updat estim accordingli reiter buy view
current valuat attract give adequ valu pipelin asset
commerci prepared gvhd underway
supplement fda applic jakafi steroid-refractori acut graft-versus-
host diseas sr-agvhd receiv pdufa prescript user fee act action date
februari remain confid readi launch believ
top stem cell transplant center account transplant allow
target launch current salesforc ramp pre-empt physician educ
convers make sure jakafi formulari sr-agvhd underway pivot
data reach sr-agvhd vs best support care reach sr chronic gvhd
itacitinib treatment-nav agvhd expect
remain confid studi due prior proof-of-concept studi
treatment itacitinib inhibitor treatment-nav patient provid
spare ad potenti better toler profil patient
multipl trial readout expect
posit data pemigatinib recent updat demonstr deepen
respons second-lin cholangiocarcinoma bile duct cancer plan file fda
approv base full trial data phase trial front-lin vs gem cisplatin
begin enrol result pemigatinib bladder cancer continu
dose cohort topic ruxolitinib vitiligo also expect phase data
baricitinib atop dermat ad also anticip
full definit iqmethod sm measur see page
net dbt
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biotechnolog compani focus drug
develop hematology/oncolog
inflamm multipl market product
includ inhibitor jakafi approv
myelofibrosi polycythemia vera olumi
baricitinib approv ra eu us
iclusig cml emerg rich clinic
rate share buy see signific
valu market product jakafi ruxolitinib
mf pv see signific potenti
compani robust pipelin olumi
approv eu us ruxolitinib gvhd ad
fgfr inhibitor liquid solid
po deriv probability-adjust npv analysi includ
jakafi call jakavi ex-u mf pv jakafi/itacitnib gvhd
olumi iclusig earli pipelin also includ
approx net cash use wacc termin valu
downsid risk price object weaker-than-expect sale jakafi mf
pv unfavor efficaci and/or safeti data pipelin asset clinic trial
earlier-than-expect more-than-expect competit jakafi approv
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
